» Articles » PMID: 12373015

Influence of Growth Hormone on Accretion of Bone Mass

Overview
Journal Horm Res
Specialty Endocrinology
Date 2002 Oct 10
PMID 12373015
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Growth hormone (GH) exerts important influences on bone metabolism during lifespan. During childhood, GH is a major determinant of acquisition of bone mass and in adult life, GH partly determines the rate of bone remodelling and therefore influences maintenance of bone mineral density (BMD). Insights into the importance of GH in these respects may be obtained by studies of BMD and indices of bone remodelling in GH deficiency (GHD) of adult-onset and childhood-onset. Adult-onset GHD, usually accompanied by other features of hypopituitarism, may be associated with osteopenia and an increased fracture risk. Postulated mechanisms include GHD and gonadal steroid deficiency of unknown duration; glucocorticoid and thyroxine replacement do not appear to exert a major role. GH replacement in adult-onset GHD results in an early increment in indices of bone remodelling which persists for up to 5 years; BMD increases by 0.5-1.0 SD in males and stabilizes in females over this time period. In adolescents with GHD who traditionally discontinue GH at completion of linear growth, BMD is substantially lower than peak bone mass for a young adult population. Studies addressing the effects of continuation of GH after achievement of final height are currently underway and will provide insights into the possible need to continue GH into adult life. Such studies may confirm a role for GH in promoting continued accrual of bone mass and thereby demonstrate that cessation of GH at achievement of final height, by limiting peak bone mass, may predispose to clinically significant osteoporosis in later life. In addition to the potential importance of GH for achievement of peak bone mass, there may be a superimposed accelerated loss of BMD with advancing age similar to the situation observed in adult-onset GHD. To date, this has been difficult to assess in adult GHD of childhood-onset because the relative contributions of low peak bone mass and increased loss of bone in later life could not be distinguished.

Citing Articles

Exercise for optimizing bone health after hormone-induced increases in bone stiffness.

Hughes J, Guerriere K, Popp K, Castellani C, Pasiakos S Front Endocrinol (Lausanne). 2023; 14:1219454.

PMID: 37790607 PMC: 10544579. DOI: 10.3389/fendo.2023.1219454.


The Specificities of Elite Female Athletes: A Multidisciplinary Approach.

Castanier C, Bougault V, Teulier C, Jaffre C, Schiano-Lomoriello S, Vibarel-Rebot N Life (Basel). 2021; 11(7).

PMID: 34206866 PMC: 8303304. DOI: 10.3390/life11070622.


Summary of Expert Opinion on the Management of Children With Chronic Kidney Disease and Growth Failure With Human Growth Hormone.

Cappa M, Maghnie M, Carbone V, Chioma L, Errichiello C, Giavoli C Front Endocrinol (Lausanne). 2020; 11:587.

PMID: 33013690 PMC: 7493742. DOI: 10.3389/fendo.2020.00587.


Trabecular bone score as a skeletal fragility index in acromegaly patients.

Hong A, Kim J, Kim S, Kim S, Shin C Osteoporos Int. 2015; 27(3):1123-1129.

PMID: 26446771 DOI: 10.1007/s00198-015-3344-2.


The exon 3 polymorphism of the growth hormone receptor is a severity-related factor for osteoporosis.

Marques F, Lins T, Lima R, Fonseca R, de Franca N, Jaco de Oliveira R Endocrine. 2013; 45(3):487-96.

PMID: 23812803 DOI: 10.1007/s12020-013-0004-1.